Introduction {#s1}
============

Some individuals are at increased risk of metabolic diseases, including hypertension, coronary artery disease (CAD), and type 2 diabetes (T2D) despite a normal BMI. These individuals are often referred to as "metabolically obese, normal weight" ([@B1],[@B2]). The mechanisms that cause an adverse metabolic phenotype in individuals of normal weight are poorly understood. One possible mediator is insulin resistance (IR), which was proposed 25 years ago as a potential link among hypertension, CAD, and T2D and which led to the idea of a "metabolic syndrome" ([@B3]).

Three broad categories of unusually severe IR exist caused by mutations in single genes. The mechanisms underlying these monogenic disorders are better understood ([@B4]) compared with the "common" IR for which genome-wide association studies (GWAS) have identified numerous associated alleles. The first category is lipodystrophy, a partial or complete lack of subcutaneous fat, most often caused by mutations in genes involved in fat cell differentiation or function (e.g., *PPARG* \[[@B5]\]) or, rarely, by more distal insulin signaling defects (*AKT2* \[[@B6]\]). Lipodystrophy is characterized by varying degrees of adipose tissue deficiency, severe dyslipidemia (high triglycerides, low HDL cholesterol \[HDL-C\]), severe fatty liver, low adiponectin, low sex-hormone-binding globulin (SHBG), and an increased risk of hypertension, CAD, and T2D ([@B7]--[@B9]). The uncoupling of indices of adiposity from severe metabolic disease in lipodystrophy is one of the key pieces of evidence for the notion that expandable, metabolically flexible adipose tissue is essential for health ([@B9]). The second category includes syndromes (such as those caused by leptin deficiency) in which IR is driven by a primary effect on energy homeostasis, leading to severe obesity and a biochemical profile resembling the "common" metabolic syndrome. These disorders are usually characterized by hyperphagia from an early age and extreme childhood obesity and are most commonly attributable to mutations affecting key components of hypothalamic neurocircuitry ([@B10]). The third category includes syndromes caused by loss-of-function mutations in the insulin receptor called "receptoropathies." These disorders are characterized by extremely high insulin levels but lack dyslipidemia and fatty liver disease and often exhibit normal or raised levels of plasma adiponectin and SHBG ([@B11]), quite unlike common IR.

In this study, we tested the hypothesis that common alleles associated with IR influence the metabolic outcomes of monogenic forms of IR, including increased risk of hypertension, CAD, and T2D. We aimed to use the subclinical phenotypes that characterize different forms of monogenic IR to determine whether mechanistically informative subphenotypes of common IR may be identified. Recent GWAS have identified 19 common genetic variants associated with indices of IR based on fasting plasma insulin concentration ([@B12],[@B13]). One of these variants is in the *FTO* gene, and the allele associated with greater risk of IR is associated with higher BMI and an adverse metabolic profile ([@B12]). This pattern is closely similar to that of severe obesity. A second common variant, near the *IRS1* gene, is associated with IR, lower total body fat content, lower subcutaneous fat amount, dyslipidemia, lower adiponectin, and increased risk of diabetes and CAD ([@B14]). This pattern is closely similar to that of "lipodystrophic" IR, but quite unlike the severe obesity or "receptoropathy" patterns.

We show that a cluster of 11 variants among 19 common genetic variants associated with indices of IR are collectively associated with metabolic features similar to those of lipodystrophy, including a *lower* BMI, higher visceral-to-subcutaneous adipose tissue ratio, and a predisposition to T2D, hypertension, and CAD. This finding provides genetic evidence for an association between reduced subcutaneous adiposity and BMI and increased risk of "obesity-associated" diseases.

Research Design and Methods {#s2}
===========================

Selection of Genetic Variants {#s3}
-----------------------------

We selected the 19 independent single nucleotide polymorphisms associated with fasting insulin as reported in the most recent Meta-Analysis of Glucose and Insulin Consortium (MAGIC) GWAS ([@B12]) ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). Of these 19 variants, 14 were detected at genome-wide significance before correction for BMI, and 5 only reached significance after correcting for BMI. All were at least nominally associated with uncorrected fasting insulin at *P* \< 1.19 × 10^−5^. Although not the optimum measure of IR, collectively these variants are associated with gold standard measures of IR ([@B15]). For comparison, we selected the 32 variants associated with BMI from the Genetic Investigation of ANthropometric Traits (GIANT) consortium ([@B16]) ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)).

Metabolic Traits {#s4}
----------------

We used summary statistics data from publicly available GWAS ([Table 1](#T1){ref-type="table"}).

###### 

Source of summary statistic data from GWAS of metabolic traits and their changes in monogenic forms of IR

  Trait                                            Consortia    Maximum *N* (all or cases vs. controls)   Reference   Monogenic obesity[\*](#t1n1){ref-type="table-fn"}   Monogenic lipodystrophy[\*](#t1n1){ref-type="table-fn"}   Monogenic receptoropathy[\*](#t1n1){ref-type="table-fn"}
  ------------------------------------------------ ------------ ----------------------------------------- ----------- --------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------
  Nondisease metabolic traits                                                                                                                                                                                                       
   SHBG                                            CHARGE       21,000                                    ([@B22])    --                                                  --                                                        0/+
   HDL-C                                           GLGC         99,900                                    ([@B17])    --                                                  --                                                        0
   Adiponectin                                     ADIPOGEN     29,346                                    ([@B21])    --                                                  --                                                        0/+
   BMI                                             GIANT        123,865                                   ([@B16])    \+                                                  --                                                        0
   VATSAT ratio                                    VATGen       10,557                                    ([@B18])    \+                                                  \+                                                        0
   CT-measured hepatic steatosis                   GOLD         7,176                                     ([@B19])    \+                                                  \+                                                        0
   ALT                                             ---          55,474                                    ([@B20])    \+                                                  \+                                                        0
   Triglyceride                                    GLGC         96,598                                    ([@B17])    \+                                                  \+                                                        0
  Metabolic disease and disease-related outcomes                                                                                                                                                                                    
   T2D                                             DIAGRAM      12,171 vs. 56,862                         ([@B26])    \+                                                  \+                                                        \+
   CAD                                             CARDIoGRAM   40,365 vs. 63,714                         ([@B25])    \+                                                  \+                                                        0
   Systolic blood pressure                         ICBP         69,828                                    ([@B24])    \+                                                  \+                                                        0
   Diastolic blood pressure                        ICBP         69,816                                    ([@B24])    \+                                                  \+                                                        0
   cIMT                                            CHARGE       31,210                                    ([@B23])    \+                                                  \+                                                        0
   Carotid plaque                                  CHARGE       25,179                                    ([@B23])    \+                                                  \+                                                        0

VATSAT, visceral-to-subcutaneous adipose tissue.

\*+ refers to high in condition, -- refers to low in condition, and 0 refers to not changed.

Study Design {#s5}
------------

### Selection of Nondisease Metabolic Traits {#s6}

We selected eight traits known to be nondisease markers of the three different subtypes of monogenic IR ([Table 1](#T1){ref-type="table"}). These traits were HDL-C ([@B17]) and triglyceride levels ([@B17]) to represent dyslipidemia; BMI ([@B16]) and visceral-to-subcutaneous adipose tissue ratio ([@B18]) to represent adiposity; computed tomography (CT)-measured hepatic steatosis ([@B19]) and plasma levels of the liver enzyme alanine transaminase (ALT) ([@B20]) to represent the spectrum of nonalcoholic fatty liver disease; and circulating levels of the fat cell--derived protein adiponectin ([@B21]) and circulating levels of the liver-derived protein SHBG ([@B22]).

### Selection of Metabolic Disease Outcome {#s7}

We selected six metabolic diseases or disease-related outcomes known to be increased in some forms of monogenic IR. These outcome traits represent the diseases that the metabolic syndrome tries to predict: carotid intima-media thickness (cIMT) and carotid plaque as surrogates of atherosclerosis ([@B23]); diastolic and systolic blood pressure to represent hypertension ([@B24]); and CAD ([@B25]) and T2D ([@B26]). Further details of disease outcomes are available in [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1).

Cluster Analysis of Fasting Insulin--Associated Genetic Variants Using Nondisease Metabolic Traits {#s8}
--------------------------------------------------------------------------------------------------

We used a hierarchical clustering analysis and the eight nondisease traits to group fasting insulin variants into those likely to predispose to IR through similar mechanisms. This method is used for clustering gene expression profiles to discover coregulated and functionally related genes or to identify subtypes of related samples ([@B27]) and is similar to principal components analyses. This approach was recently used to group 37 genetic variants associated with T2D into those with primary effects on glucose sensing, β-cell dysfunction, or IR ([@B28]). We used the summary statistics of the 19 fasting insulin variants ([@B12]) from the GWAS of the 8 nondisease metabolic traits ([Table 1](#T1){ref-type="table"}) and aligned all effects to the fasting insulin increasing alleles. We used the "pvclust" package in R, which performs agglomerative hierarchical clustering and bootstrapping, to estimate the stability and significance of the resulting clusters ([@B29]). In this method, variants are assigned to clusters based on associations with a similar set of phenotypes. We used Euclidean metrics in the algorithm to calculate pairwise distance between the effect sizes on biomarker levels of the variants as input data. We used "ward" as a cluster method. The *P* values in this method represent the relative frequency of how often the variants are in the same cluster.

Meta-analysis of Fasting Insulin-- and BMI-Associated Genetic Variants Against Nondisease Metabolic Traits and Metabolic Disease Outcomes {#s9}
-----------------------------------------------------------------------------------------------------------------------------------------

We calculated genetic risk scores of variants that clustered together by meta-analyzing summary statistics of genotype-phenotype associations across the variants for a given trait. This method has been described and validated previously ([@B30]). We repeated this analysis for the 32 variants known to be associated with BMI. We compared per-allele effects of fasting insulin clusters to each other and to per-allele effects of the BMI variants using Z test. We considered a conservative nominal *P* ≤ 0.001 as significant, corresponding to a Bonferroni correction of 42 tests (14 traits tested \[8 nondisease metabolic traits and 6 metabolic disease outcomes\] against 3 clusters).

Sensitivity Analyses {#s10}
--------------------

We performed three sets of sensitivity analyses to test whether weighting changes the association of each genetic risk score with nondisease marker and disease outcome traits. We calculated the genetic risk score using summary statistics of genotype-phenotype associations weighted in three different ways: *1*) by each variant's corresponding effect size with the primary trait (fasting insulin) as weight; *2*) by each variant's corresponding effect size with the primary trait (fasting insulin) using the formula used before ([@B21]),where refers to the effect of variant~i~ on the outcome data, is the associated SE estimate, and is the effect of variant~i~ on fasting insulin; and *3*) by weighting variants and taking into account allele frequencies,where is the effect allele frequency of the variant~i~ and is the frequency of the other allele for variant~i~.

Results {#s11}
=======

A Cluster of 11 Fasting Insulin--Associated Genetic Variants Resembles the Metabolic Profile of Monogenic Lipodystrophic IR {#s12}
---------------------------------------------------------------------------------------------------------------------------

Using the 8 nondisease metabolic traits of monogenic IR and all 19 common fasting insulin associated genetic variants ([@B12]), we identified 11 genetic variants that together could be distinguished statistically from the remaining 8 variants (*P* of the robustness of the branching event = 96%) ([Fig. 1](#F1){ref-type="fig"}). This cluster of 11 common variants included those in or near the genes *IRS1*, *GRB14*, *ARL15*, *FAM13A*, *LYPLAL1*, *PEPD*, *PDGFC*, *RSPO3*, *PPARG*, *TET2*, and *ANKRD55*. The 11-variant genetic risk score was associated with all 8 nondisease markers of monogenic IR. As expected, given the traits used to define the cluster, fasting insulin--raising alleles were associated with higher triglycerides (β = 0.018; *P* = 4 × 10^−29^), lower HDL-C (β = −0.020; *P* = 7 × 10^−37^), greater hepatic steatosis (β = 0.021; *P* = 3 × 10^−4^) higher ALT (β = 0.002; *P* = 3 × 10^−5^), lower SHBG (β = −0.010; *P* = 9 × 10^−13^), and lower adiponectin (β = −0.015; *P* = 2 × 10^−26^). In contrast to this adverse metabolic profile, the fasting insulin--raising alleles were associated with *lower* BMI (per-allele β = −0.008; *P* = 7 × 10^−8^) ([Table 2](#T2){ref-type="table"}). The fasting insulin--raising alleles were also associated with increased visceral-to-subcutaneous adipose tissue ratio (β = −0.015; *P* = 6 × 10^−7^) ([Table 2](#T2){ref-type="table"}). The association with visceral-to-subcutaneous adipose tissue ratio was primarily driven by reduced subcutaneous adipose tissue (−0.014; 2 × 10^−6^). As an example, these effects meant that the 5.5% of individuals carrying ≥17 fasting insulin--raising alleles were 0.30 kg/m^2^ of BMI slimmer but had triglyceride levels 0.16 SD units higher and HDL levels 0.18 SD units lower, compared with the 5.5% of individuals carrying ≤9 fasting insulin--raising alleles. Note that the units for each biomarker may be different depending on the source of GWAS data ([Table 2](#T2){ref-type="table"}).

![Cluster analysis of fasting insulin variants using eight traits known to be nondisease metabolic traits of monogenic IR, including those representing dyslipidemia (HDL and triglyceride), adiposity (BMI and visceral-to-subcutaneous adipose tissue ratio), fatty liver (CT-measured hepatic steatosis and the liver enzyme ALT), and adiponectin and SHBG levels. The dendrogram (*A*) shows that 11 variants and 5 variants are grouped in two significant clusters (the approximate unbiased values = 96% \[*P* = 0.04\] and 98% \[*P* = 0.02\], respectively). The heatmap (*B*) shows this cluster is consistent with monogenic lipodystrophic IR; the stronger the green color, the stronger the effect of the insulin-raising allele with reduced trait levels; the stronger the pink color, the stronger the effect of the insulin-raising allele with higher trait levels. VATSAT, visceral-to-subcutaneous adipose tissue ratio; NAFLD, nonalcoholic fatty liver disease.](4369fig1){#F1}

###### 

Results of genotype risk score analysis of the 11 "lipodystrophy-like" variants

  Category/trait                                   Unit          Per-allele β   95% CI           *P*               *N*
  ------------------------------------------------ ------------- -------------- ---------------- ----------------- -------------------
  Nondisease metabolic traits of monogenic IR                                                                      
   SHBG (BMI adjusted)                             Natural log   −0.010         −0.012, −0.008   **9 × 10^−13^**   21,000
   HDL-C                                           SD            −0.020         −0.024, −0.016   **7 × 10^−37^**   99,900
   Adiponectin (BMI adjusted)                      log           −0.015         −0.017, −0.013   **2 × 10^−26^**   29,346
   BMI                                             SD            −0.008         −0.012, −0.004   **7 × 10^−8^**    123,865
   VATSAT ratio                                    z-score       0.015          0.009, 0.021     **6 × 10^−7^**    10,557
   CT-measured hepatic steatosis                   SD            0.021          0.009, 0.033     **3 × 10^−4^**    7,176
   ALT                                             log~10~       0.002          0.001, 0.003     **3 × 10^−5^**    55,474
   Triglyceride                                    SD            0.018          0.014, 0.022     **4 × 10^−29^**   96,598
  Metabolic disease and disease-related outcomes                                                                   
   T2D                                             OR            1.043          1.031, 1.055     **5 × 10^−13^**   12,171 vs. 56,862
   CAD                                             OR            1.013          1.007, 1.019     **1 × 10^−5^**    40,365 vs. 63,714
   Systolic blood pressure (BMI adjusted)          mmHg          0.135          0.072, 0.198     **2 × 10^−5^**    69,828
   Diastolic blood pressure (BMI adjusted)         mmHg          0.075          0.036, 0.114     **2 × 10^−4^**    69,816
   cIMT                                            log           0.000          −0.002, 0.002    0.70              31,210
   Carotid plaques                                 OR            1.005          0.991, 1.019     0.50              25,179

The 8 nondisease metabolic traits were used to select the 11 variants, so associations are not independent of the clustering process. The metabolic disease outcomes were not used in the clustering process and so represent independent tests. VATSAT, visceral-to-subcutaneous adipose tissue. *P* values ≤ 0.001 are in bold.

A second cluster of five genetic variants (*P* of the robustness of the branching event = 98%) included those in or near the genes *YSK4*, *UKRF1BP1*, *TCF7L2*, *IGF1*, and *HIP1* ([Fig. 1](#F1){ref-type="fig"}) but was not associated with any of the nondisease markers of monogenic IR (all *P* values \> 0.001) except higher BMI (β = 0.012; *P* = 3 × 10^−6^) ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)) and so was not studied further. Variants in or near *FTO*, *GCKR*, and *PPP1R3B* did not cluster with other variants, most likely because of their primary effects on BMI, triglycerides, and HDL-C, respectively ([Fig. 1](#F1){ref-type="fig"}; [Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). The variant in *FTO* provides a proof-of-principle example of how a BMI-associated variant can be separated from variants associated with fasting insulin through mechanisms other than higher BMI. The *GCKR* variant shows how the use of multiple metabolic phenotypes can be used to separate out different mechanisms---we know this variant is likely to operate through a particular mechanism linking glucose to lipid metabolism ([@B31]) in the liver and it was individually associated with multiple liver-based phenotypes ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)).

A Cluster of 11 Fasting Insulin Associated Variants Resembling Lipodystrophy Is Associated With Metabolic Disease Outcomes {#s13}
--------------------------------------------------------------------------------------------------------------------------

The genetic risk score consisting of the 11 fasting insulin variants was associated with 4 of the 6 metabolic disease outcomes, in directions consistent with the lipodystrophy-like phenotype. The 11-variant genetic risk score was associated with a higher risk of T2D (per-allele odds ratio \[OR\] = 1.043; 95% CIs 1.031, 1.055; *P* = 5 × 10^−13^) and CAD (per-allele OR = 1.013; 95% CIs 1.007, 1.019; *P* = 1 × 10^−5^), and higher systolic (β = 0.135; 95% CIs 0.072, 0.198; *P* = 2 × 10^−5^) and diastolic blood pressure (β = 0.075; 95% CIs 0.036, 0.114; *P* = 2 × 10^−4^) but was not associated with cIMT or risk of carotid plaques (*P* values \> 0.001) ([Fig. 2](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). As an example, these effects meant that individuals carrying ≥17 fasting insulin--raising alleles (5.5% of the population) were 0.30 kg/m^2^ slimmer but had an estimated OR of T2D and coronary heart disease of 1.46 and 1.12, respectively, and an estimated increase in systolic and diastolic blood pressure of 1.21 and 0.67 mmHg, respectively, compared with individuals carrying ≤9 fasting insulin--raising alleles (5.5% of the population) ([Supplementary Fig. 1*A* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). Sensitivity analyses using three different methods to weight individual variants provided very similar results ([Supplementary Table 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)), and exclusion of the previously reported variant near *IRS1* did not appreciably change the results ([Supplementary Table 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)).

![Forest plots of the effect of the 11 "lipodystrophy-like" variants on six metabolic disease outcomes. The *x*-axis is the effect size per fasting insulin--increasing alleles on each trait. The dashed line is the null effect. For cIMT, actual effects ranged from −0.003 to 0.003 but here are shown rounded to two decimal places. FE, fixed effect.](4369fig2){#F2}

Comparing the Cluster of 11 Fasting Insulin Variants Resembling Lipodystrophy to the 32 Known BMI Variants {#s14}
----------------------------------------------------------------------------------------------------------

We next compared the per-allele effects of the cluster of fasting insulin--associated variants with the per-allele effects of the known 32 BMI variants. They were both associated with nondisease metabolic traits, with two notable differences. *1*) The cluster of 11 fasting insulin variants was associated with higher visceral-to-subcutaneous adipose tissue ratio, whereas the 32-variant BMI group was associated with lower visceral-to-subcutaneous adipose tissue ratio ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). *2*) The 32-variant BMI cluster was not associated with CT-measured hepatic steatosis ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). Compared with the 32-BMI-variant risk score, the 11 variant fasting insulin cluster was more strongly associated with risk of T2D (BMI per-allele OR = 1.021 \[1.016--1.028\], *P* = 1 × 10^−12^; the 11-variant cluster per-allele OR = 1.043 \[1.031--1.055\], *P* = 5 × 10^−13^; *P* of difference = 0.002) but did not have detectably different per-allele associations with CAD ([Supplementary Fig. 1*B* and *D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1); [Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1)). As with the fasting insulin cluster, the 32-BMI-variant score was not associated with cIMT or carotid plaque.

Discussion {#s15}
==========

We have shown that common alleles associated with IR (as measured by fasting insulin) are associated with metabolic outcomes of monogenic forms of IR. Most notably, a cluster of 11 common genetic variants show a pattern of metabolic trait associations consistent with a common, subtle "lipodystrophy-like" phenotype, conferring an increased risk of hypertension, T2D, and CAD despite a lower BMI. Our findings are consistent with "adipose expandability" hypotheses ([@B32]), which propose that the expandability of adipose tissue is limited and that it is the exceeding of this intrinsic storage capacity, which is partly genetically determined, which contributes to common forms of IR. More broadly, our results suggest that there is a partly genetic basis to the widely reported "metabolically obese, normal-weight" phenotype ([@B1],[@B2]).

Our study has a number of implications. First, our results provide evidence that the 11 variants associated with a lipodystrophy-like metabolic phenotype exert their effect through a primary role in adipose tissue. Consistent with this notion, the genetic loci involved include *PPARG*, which is the most important transcription factor in the control of adipogenesis ([@B33],[@B34]) and which harbors dominant negative mutations in a Mendelian subtype of partial lipodystrophy featuring reduced body fat and severely dyslipidemic IR ([@B35]). Thus, although our findings do not prove causality in the observed associations, they indicate that future in vitro and in vivo functional studies could start with adipose tissue--based hypotheses and the genes located near the 11 variants highlighted by our cluster analysis.

Second, we have shown that using phenotypic features of monogenic diseases may be an informative method to help understand likely mechanisms of more common, less penetrant alleles. We show that common fasting insulin--associated variants identified by GWAS may be clustered into discrete subgroups using a panel of nondisease markers that discriminate different forms of monogenic severe IR ([@B9]). These markers included circulating factors such as lipids, adiponectin, and SHBG as well as adiposity. The approach is analogous to that recently used to cluster T2D variants into different groups according to subclinical phenotypes ([@B28]).

Third, our results raise the possibility that individuals carrying large numbers of fasting insulin--raising alleles at these 11 loci represent human "in vivo" models of adipose tissue dysfunction. Although individually the common alleles have very subtle effects, ∼5.5% of people in the general population will have an ∼1.46 increased odds of T2D and 1.12 increased odds of CAD compared with people from the other end of the distribution of these alleles, but these people will have lower BMIs. More in depth studies of the fat distribution and adipose tissue morphology and function of these individuals may lead to further understanding of the BMI-independent mechanisms of metabolic disease.

Finally, if more lipodystrophy-like variants are identified through ongoing genetic studies, testing such variants in combination may have clinical utility in identifying individuals at high genetic risk of "adipose failure." These individuals have previously been termed the metabolically obese, normal weight ([@B1],[@B2]). In such people, it may be appropriate to use lower BMI-based thresholds for access to adipose offloading therapies, including oral weight loss medications and bariatric surgery, as they have the potential to develop metabolic disease at a lower BMI.

Our study has some notable strengths and some limitations. The main strength is that we used a genetic approach to dissect the associations between multiple metabolic traits. While we cannot be certain of the primary trait involved, genetic variants are far less susceptible to confounding and bias than most nongenetic measures, and so our results provide strong support for a causal link between the traits tested. The second main strength is that we used a wider panel of phenotypic features than IR alone as a basis for subgrouping fasting insulin--associated variants while, critically, constraining this panel to those markers that have shown utility in discriminating different forms of monogenic IR.

There are some important limitations to our results. Firstly and most importantly, the associations we observed, while statistically very robust, are very subtle in terms of effects on metabolic traits. More than 50,000 individuals were required to identify the variants associated with fasting insulin, and so they explain only a small proportion of the variation in IR and the other metabolic traits we have examined. Hence our results do not provide evidence that the "polygenic lipodystrophy-like" phenotype is the primary mechanism of IR and its link to metabolic disease but instead establish the principle that reduced adipose expandability is one mechanism that links these traits in the general population. Further genetic discoveries will help us understand the relative role of this mechanism. A second limitation was that our hierarchical clustering approach was based on eight nondisease markers that are correlated with each other, and many of the same studies and individuals contributed to multiple phenotypes. Further studies with individual level data will be needed to able to account for these correlations. However, using two correlated, but not perfectly correlated measures, such as adiponectin and SHBG, will increase the resolution of the clustering approach, as recently demonstrated in a similar approach to cluster T2D variants by correlated glycemic traits. A third limitation is that the fasting insulin--associated variants were ascertained from truncated distributions of glycemic traits because the MAGIC study excluded individuals with fasting glucose above 7.0 mmol/L to limit the possibility of confounding effects from diabetes disease processes and treatments. This ascertainment issue may explain why the diabetes risk allele at *TCF7L2* and possibly other alleles may be associated with apparently greater insulin sensitivity---carriers of T2D risk alleles will need to be subtly more insulin sensitive to remain nondiabetic, for example. It is therefore reassuring that *TCF7L2* does not cluster with the 11 "lipodystrophy-like" variants. A fourth main limitation is that some of the phenotypes used were not gold standard measures. We used genetic variants associated with fasting insulin, which is not the best measure of IR, but we note that the genetic risk score we used is strongly associated with more direct measures of IR in the accompanying article ([@B15]). We also used cIMT and carotid plaque as surrogates for atherosclerosis, and it is well-known that these traits are suboptimal measures of atherosclerosis ([@B23]). The lack of association between the cluster of 11 fasting insulin variants and cIMT or carotid plaque could be due to reduced statistical power due to sample size or the intraindividual variation and measurement error involved in these phenotypes. Alternatively, the lack of association could be because the fasting insulin--associated variants predispose to CAD through pathways other than those captured by cIMT and carotid plaque measures.

In summary, the group of genetic variants associated with a "lipodystrophy-like" phenotype provides evidence that subtle genetically influenced higher visceral-to-subcutaneous adipose tissue ratio, fasting insulin, and dyslipidemia in combination can increase the risk of hypertension, CAD, and T2D in the absence of increased BMI. Our results provide genetic evidence for a link between the three diseases of the "metabolic syndrome." Our results may help elucidate the mechanistic pathways of how common genetic loci are linked to IR and the mechanisms behind how some individuals can remain relatively healthy despite obesity while others are susceptible to heart disease and diabetes despite relative leanness.

Our results highlight the potential role of adipose tissue dysfunction as one of the underlying mechanisms for IR, hypertension, T2D, and CAD.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-0318/-/DC1>.

See accompanying article, p. 4004.
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